Inclusion Criteria:

• Male and female patients >18 years of age with advanced, histologically-confirmed solid tumors refractory to standard therapy or for which no standard therapy exists.
• Patients must have measurable or evaluable disease.
• Patients must not have received prior chemotherapy or radiation for >/= 4 weeks before study enrollment.
• Patients may be entered if they have received prior radiation therapy involving </= 30% of the bone marrow. Any prior radiation therapy must have been administered >/= 4 weeks before study enrollment and the patient must be recovered from the acute toxic effects of the treatment prior to study entry.
• Patients may be enrolled with a history of treated brain metastases that are clinically stable for >/= 4 weeks prior to enrollment.
• ECOG performance status of </= 2.
• Life expectancy of greater than 12 weeks.
• Patients must have acceptable organ and marrow function at screening and pre-dose visits.
• Electrocardiogram without evidence of clinically significant conduction abnormalities or active ischemia as determined by the investigator.
• The effects of IT-101 on the developing human fetus are unknown, therefore, women of childbearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Women who are pregnant or lactating.
• Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
• Patients with a pre-therapy ejection fraction by echocardiogram (ECHO) of < 45%
• Patients with serum amylase or lipase > upper limit of normal (ULN)
• Patients with known Gilbert's disease.
• Patients with previous high dose chemotherapy with autologous stem cell rescue bone marrow transplantation.
• Use of any investigational agents within 4 weeks of study enrollment.
• Metastatic disease to the CNS requiring treatment or radiation therapy.
• Patients with known untreated brain metastases or treated brain metastases that have not been stable >/= 4 weeks prior to study enrollment.
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, as determined by the investigator.
• The presence of active coagulation disorder.
• Patients with marked baseline prolongation of QT/QTc interval (QTc interval > 470) using the Fridericia method as a main method of QTc analysis
• Refractory (no response to treatment) to a prior treatment with a topoisomerase I inhibitor (relapsed [return of symptoms and signs of disease after a period of improvement] to prior therapy is acceptable).